The company’s loss from operations for the second quarter of 2011 was $6.58m, compared to $4.3m for the same period in 2010.
For the six months ended 30 June 2011, the company reported a net loss of $12.39m, compared to $9.78m for the same period in 2010.
Acadia Pharma’s loss from operations was $12.45m for the six months of 2011, compared to $9.79m for the same period in 2010.
Acadia Pharma CEO Uli Hacksell said they continue to enroll patients in the ongoing -020 Phase III efficacy, tolerability and safety study and the -015 Phase III open-label safety extension study.